Comparative Pharmacology
Head-to-head clinical analysis: CARDIOQUIN versus PACERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOQUIN versus PACERONE.
CARDIOQUIN vs PACERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class IA antiarrhythmic agent; blocks sodium channels, slows phase 0 depolarization, prolongs action potential duration, and increases effective refractory period. Also exhibits anticholinergic and negative inotropic effects.
Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.
Quinidine gluconate extended-release: 324-648 mg orally every 8-12 hours. Quinidine sulfate immediate-release: 200-400 mg orally every 6 hours. Quinidine sulfate extended-release: 300-600 mg orally every 8-12 hours. Maximum dose: 3-4 g/day.
Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in patients with normal renal function. Prolonged in renal impairment (up to 16-40 hours) and heart failure, requiring dose adjustment.
Biphasic: initial 3-10 days; terminal elimination half-life 40-58 days (mean ~53 days) due to extensive tissue distribution and slow release from fat. Clinical context: steady-state achieved in 2-4 months without loading dose.
Renal: 60-80% as unchanged drug and metabolites (primarily hydroxylated metabolites). Biliary/fecal: 20-40%.
Primarily hepatic metabolism (CYP3A4, CYP2C8) to desethylamiodarone (active). Renal elimination of drug and metabolites: <1% of unchanged drug; ~40% of dose as metabolites. Fecal elimination: ~70% of dose as metabolites, with some parent drug.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent